Health Canada released a revised Guidance Document: Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs on June 28, 2019, effective immediately. Revisions include clarifying additions on the requirements for cross-licensed products for an Administrative Certification Form and Letter of Authorization, a Drug Notification form and labelling.
Health Canada has also released an updated Good Label and Package Practices Guide for Prescription Drugs. The June 21, 2019 update introduces only administrative edits to the 2016 guidance on labelling and packaging of prescription pharmaceuticals, biologics, and radiopharmaceuticals under Health Canada’s Plain Language Labelling Initiative.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More